How are these compounds
scientifically different?
Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.
This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.
Target & Mechanism Comparison
Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.
← Scroll to see all compounds →
| Target | Selank | DSIP |
|---|---|---|
| ✓ | — | |
| — | ✓ |
What These Compounds Share
Key Differences
Compound Detail
Selank
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Heptapeptide · 7 amino acids · Synthetic analogue of tuftsin
Tap a target above for a plain-language explanation.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (3) →
Russian clinical trial literature, head-to-head vs. phenazepam. Selank showed pronounced anxiolytic and mild nootropic effects, persisting up to a week after the last dose.
Supports: experimental_research, human_administration_status
Randomized, head-to-head vs. medazepam. Anxiolytic effects similar between arms; Selank additionally showed antiasthenic and psychostimulant effects. Reduced leu-enkephalin half-life correlated with disease severity and improved with Selank treatment.
Supports: experimental_research, human_administration_status
NOT a head-to-head Selank-vs-phenazepam comparison -- this tests Selank as an add-on to phenazepam vs. phenazepam alone. Combination produced earlier improvement and reduced phenazepam's side effects (attention/memory impairment, sedation, sexual disturbance) both during and after tranquilizer withdrawal.
Supports: experimental_research
DSIP
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
Nonapeptide · 9 amino acids · Originally isolated as an endogenous neuropeptide
Tap a target above for a plain-language explanation.
View Research Sources (2) →
Supports: mechanism_summary, research_limitations
Authors reported the statistically significant effects were weak, with some possibly attributable to incidental placebo-group changes.
Supports: research_limitations, human_administration_status
Common Research Comparisons
Frequently studied groupings — not recommendations.
Browse more compounds
5-Amino-1MQ
NNMT inhibitor
BPC-157
Gastric pentadecapeptide
Cagrilintide
Long-acting amylin analogue
CJC-1295
Modified GHRH analogue
DSIP
Neuropeptide
Epithalon
Synthetic tetrapeptide
GHK-Cu
Copper-binding tripeptide
GHRP-2
GH-releasing peptide / GH secretagogue
Glutathione
Endogenous antioxidant tripeptide
HCG
Glycoprotein hormone
IGF-1 LR3
IGF-1 receptor agonist (engineered analogue)
Ipamorelin
GH secretagogue
Kisspeptin-10
Kisspeptin fragment
KPV
α-MSH-derived tripeptide
Melanotan I
α-MSH analogue
Melanotan II
Cyclic melanocortin agonist
MOTS-c
Mitochondrial-derived peptide
NAD+
Cellular redox cofactor
PT-141
Cyclic melanocortin receptor agonist
Retatrutide
Triple receptor agonist
rHGH (Somatropin)
Growth hormone receptor agonist
Selank
Synthetic tuftsin analogue
Semaglutide
GLP-1 receptor agonist
Semax
Synthetic ACTH-fragment analogue
Sermorelin
GHRH fragment analogue
SS-31
Mitochondria-targeting tetrapeptide
Tesamorelin
Stabilised GHRH analogue
Thymosin Alpha-1
Thymic peptide
Thymosin Beta-4 (TB-4)
Thymosin Beta-4
Tirzepatide
Dual incretin receptor agonist